Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Go back to Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 55.42 -0.23 (0.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.65 | 52 Week High | $17.00 | |||
| Open | $56.07 | 52 Week Low | $3.55 | |||
| Day High | $56.34 | P/E | N/A | |||
| Day Low | $55.11 | EPS | $-1.33 | |||
| Volume | 574,088 | |||||
